Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical need, with emphasis on cardiovascular and inflammatory indications. Its only marketed product is ARCALYST, a biologic sold in the United States for recurrent pericarditis and certain rare autoinflammatory diseases, while its pipeline includes additional IL-1-related and immunology assets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueARCALYST, the company's marketed IL-1 trap therapy sold in the U.S. through specialty pharmacies.
Approved uses of ARCALYST in recurrent pericarditis, CAPS, and DIRA that drive current sales.
KPL-387 and related programs being developed for recurrent pericarditis and other inflammatory diseases.
Earlier-stage immunology and cardiovascular programs such as KPL-1161 and other assets.
Products
Reported · share of revenue- Products98.5 %
- Collaboration1.5 %
Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Kiniksa sells primarily to a select network of third-party specialty pharmacies and logistics partners, which then dispense ARCALYST to patients by mail. Demand is driven by physicians treating rare inflammatory and cardiovascular diseases, while reimbursement depends on payors and insurers that determine access and coverage. Because the company has only one commercial product, customer concentration and channel execution are central to the business model.
They buy ARCALYST for distribution, patient support, and prescription fulfillment, making them the core commercial channel.
Cardiologists, rheumatologists, and specialists prescribe ARCALYST for approved rare-disease indications.
Patients with painful inflammatory cardiovascular disease who need ongoing biologic treatment.
Small patient groups using ARCALYST for approved orphan indications.
They do not buy the drug directly but determine reimbursement, coverage, and patient access.
Strategy
Kiniksa's strategy is to expand ARCALYST commercialization in recurrent pericarditis while maintaining access and reimbursement support through its specialty pharmacy network. At the same time, it is advancing follow-on IL-1 and immunology programs to reduce dependence on a single product and broaden its long-term pipeline. Capital discipline remains important because the company expects continued spending on manufacturing, sales infrastructure, and clinical development.
It is the company's only commercial product and main revenue driver.
Rare-disease demand depends on coverage, pricing, and specialty pharmacy execution.
A broader pipeline reduces single-product dependence and supports future growth.
Geography
The company is headquartered in the United States, with executive offices in Massachusetts and a registered office in London following its 2024 redomiciliation to the UK. Commercial revenue is currently generated almost entirely in the United States because ARCALYST is approved for sale only there. The company also maintains subsidiaries and tax presence in the UK, Switzerland, Germany, and France to support development, IP ownership, and international structuring.
Risks
The company is highly dependent on ARCALYST, so any slowdown in uptake, reimbursement pressure, or competitive entry could materially affect revenue. Its business also relies on third parties for manufacturing, logistics, and specialty pharmacy distribution, which creates supply and execution risk in a regulated biologics market. Clinical development, regulatory approval, and the ability to fund operations remain important risks because the pipeline is still early and the company may need additional capital.
- Dependence on ARCALYST commercializationImpact: HighLikelihood: Medium
The company has one marketed product, so any demand or access disruption can materially affect revenue.
Exposure: U.S. rare-disease biologic sales
- Third-party manufacturing and supply chain relianceImpact: HighLikelihood: Medium
Commercial and clinical supply are outsourced, and biologic inputs can be scarce or single-sourced.
Exposure: Product availability and launch execution
- Reimbursement and payor pressureImpact: MediumLikelihood: Medium
Coverage and pricing decisions directly affect patient access and net revenue realization.
Exposure: Specialty pharmacy channel and U.S. payors
- Competition in IL-1 and inflammatory diseasesImpact: MediumLikelihood: Medium
Other drugs may offer more convenient dosing or alternative mechanisms in the same indications.
Exposure
Accounting
Judgemental itemsNet sales depend on estimates for discounts, rebates, returns, and copay assistance.
Impact: Can move quarterly revenue and gross-to-net margins.
Clinical and preclinical programs require estimates for vendor services and trial costs.
Impact: Affects operating expense timing and comparability.
The company has tax attributes and multinational structure that require judgment on realizability and positions.
Impact: Can affect tax expense and balance sheet valuation allowances.
Similar listed companies
Publicly listed companies with a comparable business focus.
Oruka Therapeutics, Inc.
ORKA · Pharmaceutical Preparations
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Aurinia Pharmaceuticals Inc.
AUPH · Pharmaceutical Preparations
KalVista Pharmaceuticals, Inc.
Pharmaceutical Preparations
KalVista Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing oral therapies for hereditary angioedema (HAE).
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026